Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
September 10 2021 - 8:00AM
Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, today
announced the appointment of Elizabeth Bekiroğlu to General
Counsel.
“Elizabeth is an accomplished leader who has
established an expertise in providing legal counsel to
biotechnology and healthcare companies,” said Adam Simpson, Chief
Executive Officer of Icosavax. “I am thrilled to begin working
alongside Elizabeth and look forward to her valuable insight as we
work to progress our clinical candidates down the development
pipeline and continue to grow the company.”
Ms. Bekiroğlu brings more than 15 years of
experience advising pharmaceutical and biotechnology companies on a
broad range of legal matters. Prior to joining Icosavax, Ms.
Bekiroğlu was Associate General Counsel at Seagen where she helped
lead and build the legal affairs group as Seagen transformed into a
multi-product, multinational company. Previously, she led the legal
function at Oncothyreon where she handled a wide range of
corporate, securities, clinical, manufacturing, licensing and
transactional matters. Prior to Oncothyreon, Ms. Bekiroğlu
served in roles of increasing responsibility at Emergent
BioSolutions and Trubion Pharmaceuticals. Ms. Bekiroğlu began
her legal career as a corporate associate at Fenwick & West LLP
and Orrick, Herrington & Sutcliffe LLP where she advised early
stage and public biopharmaceutical companies. Ms. Bekiroğlu
received her J.D. from Harvard Law School and a B.A. in Human
Biology from Stanford University.
About Icosavax
Icosavax is a biopharmaceutical company
leveraging its innovative VLP platform technology to develop
vaccines against infectious diseases, with an initial focus on
life-threatening respiratory diseases. Icosavax’s VLP platform
technology is designed to enable multivalent, particle-based
display of complex viral antigens, which it believes will induce
broad, robust, and durable protection against the specific viruses
targeted. Icosavax’s pipeline includes vaccine candidates targeting
respiratory syncytial virus (RSV), human metapneumovirus (hMPV),
and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Icosavax was formed in 2017 to advance the breakthrough VLP
technology from the Institute for Protein Design at the University
of Washington with the goal to discover, develop, and commercialize
vaccines against infectious diseases. Icosavax exclusively licensed
the VLP technology for use in several fields, including RSV and
hMPV, from the University of Washington. For SARS-CoV-2, Icosavax
has a non-exclusive, worldwide (excluding South Korea) license from
the University of Washington that will convert to an exclusive
license in North America and Europe in 2025. Icosavax is located in
Seattle.
Forward Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are forward-looking
statements. The forward-looking statements are based on our current
beliefs and expectations and include, but are not limited to: our
goal to progress our clinical candidates down the development
pipeline and to continue to grow Icosavax, and the therapeutic
potential of our VLP technology. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: the early stage of our development efforts; our
approach to the discovery and development of vaccine candidates,
which is a novel and unproven approach; potential delays in the
commencement, enrollment, and completion of clinical trials; and
other risks described in our prior filings with the Securities and
Exchange Commission (SEC), including under the heading “Risk
Factors” in our Registration Statement on Form S-1 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Media Contact: Jessica
Yingling, Ph.D.Little Dog Communications
Inc.jessica@litldog.com+1.858.344.8091
Investor Contact: Laurence
WattsGilmartin Group,
LLClaurence@gilmartinir.com+1.619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Sep 2023 to Sep 2024